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Mark W. Russell, M.D., and Barry E. Bleske, Pharm.D., FCCP
Study Objective. To determine the effects of hawthorn (Crataegus oxycantha)
on left ventricular remodeling and function in pressure overload–induced
heart failure in an animal model.
Design. Randomized, parallel, dose-ranging animal study.
Setting. University research facility.
Animals. Seventy-four male Sprague-Dawley rats; 44 were included in the
final analysis.
Intervention. Rats underwent a sham operation or aortic constriction. Rats
subjected to the sham operation were treated with vehicle (10% agar-agar),
and those subjected to aortic constriction were treated with vehicle or
hawthorn (C. oxycantha special extract WS 1442) 1.3, 13, or 130 mg/kg for
5 months.
Measurements and Main Results. Rats and their hearts were weighed, and
echocardiographic measurements were performed at baseline and at 2, 3, 4,
and 5 months after aortic constriction. Protein expression for markers of
fibrosis and for atrial natriuretic factor was also measured. Aortic
constriction increased the left ventricular:body weight ratio by 53% in
vehicle-treated rats; Hawthorn treatment did not significantly affect the
aortic constriction–induced increase in this ratio. Left ventricular volumes
and dimensions at systole and diastole significantly increased 5 months after
aortic constriction compared with baseline in rats given vehicle (> 20%
increase, p<0.05) but not in those given hawthorn 130 mg/kg (< 10%
increase). After aortic constriction, the velocity of circumferential
shortening significantly decreased in the vehicle group but not in the
medium- or high-dose groups. In the aortic constriction–vehicle group, the
induced increases in messenger RNA expression for atrial natriuretic factor
(~1000%) and fibronectin (~80%) were significantly attenuated by high-
dose hawthorn treatment by approximately 80% and 50%, respectively.
Conclusion. Hawthorn treatment exhibited modest beneficial effects on
cardiac remodeling and function during long-term, pressure overload–
induced heart failure in rats.
Key Words: hawthorn, Crataegus oxycantha, heart failure, atrial natriuretic
factor, ANF, left ventricular volume, fibronectin, animal study.
(Pharmacotherapy 2009;29(6):639–648)
Heart failure is a clinical syndrome with
diverse causes and has progressive cardiac
dysfunction as its distinguishing characteristic.1
All patients with systolic heart failure have left
ventricular dysfunction, but cardiac dysfunction
itself does not always lead to symptoms of the
disease. Left ventricular remodeling plays an
important role in the progression of chronic heart
failure. Early remodeling is an adaptive response
to the increased load on the heart and/or the loss
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of contractile components to maintain pumping
capacity. However, prolonged overload taxes the
limits of adaptive mechanisms, forcing compromises
that result in progressive deterioration of pump
function. Ultimately, the left ventricle enlarges,
and its diastolic and/or systolic function is
impaired.
Aortic constriction in rats causes chronic left
ventricular pressure overload, progressive cardiac
remodeling, and subsequent cardiac failure that
mimics heart failure in humans.2–4 Pressure
overload also induces an increase in cardiac
fibrosis, resulting in diastolic dysfunction, again
similar to findings in humans.5, 6 In addition, this
rat model leads to initial compensatory
hypertrophy that progresses to heart failure in a
predictable manner akin to the progression seen
in people. Finally, effects of angiotensin-
converting enzyme (ACE) inhibitors (and other
drugs) in this model are similar to those observed
in human heart failure.4 Overall, chronic aortic
constriction–induced pressure overload is a good
model to study the effects of drugs on the
development and progression of heart failure.
At present, an estimated 38% of the adult
population of the United States uses herbal
therapy.7 Hawthorn (Crataegus oxycantha) is a
popular botanical treatment for heart disease,
including heart failure, especially in Europe and
China. Early trials demonstrated that hawthorn
may offer modest beneficial effects in the
treatment of heart failure.8, 9 Recent trials,
however, have not shown an especially striking
benefit for heart failure that is well treated with
standard drug therapy.10, 11
We recently demonstrated that short-term
hawthorn treatment improved cardiac functions
in pressure overload–induced cardiac remodeling.12
However, whether long-term treatment with
hawthorn influences the progression of heart
failure—specifically cardiac remodeling and
fibrosis—is unknown. Therefore, the purpose of
this study was to determine the effects of
hawthorn on the progression of heart failure in a
rat model of chronic pressure overload.
Methods
Animals
Male Sprague-Dawley rats, each weighing
250–275 g, were obtained from Charles River
Laboratories (Wilmington, MA). The rats were
housed two or three to a cage, fed a standard
laboratory diet (5001; PMI Nutrition International,
Richmond, IN), given water ad libitum, and
maintained on a cycle of 12 hours light and 12
hours dark. The University Committee on Use
and Care of Animals at the University of
Michigan approved all animal protocols, which
conformed to the Guiding Principles in the Care
and Use of Animals of the American Physiological
Society.
Experimental Design
The rats were subjected to a sham operation or
aortic constriction. Rats subjected to the sham
operation were treated with vehicle (10% agar-
agar), and those subjected to aortic constriction
were treated with vehicle or three doses of
hawthorn (C. oxycantha special extract WS 1442;
Dr. Willmar Schwabe Pharmaceuticals GmbH &
Co. KG, Karlsruhe, Germany) for 5 months
beginning 1 week after aortic constriction.
Crataegus oxycantha special extract WS 1442 is
a dry extract derived from hawthorn leaves with
flowers, with a raw material:extract ratio of
4–6.6:1 using 45% (weight/weight) ethanol as
extraction solvent. The extract is adjusted to
contain 17.3–20.1% oligomeric procyanidins.
The batch we used (Ch. 289 N001) contained
18.8% oligomeric procyanidins, 2.9% flavonoids
(calculated as hyperoside), 0.4% oleanolic acid,
and 1% cyanidin (calculated as cyanidin
chloride).
The doses and administration schedule for
hawthorn were similar to those previously
described.12 In brief, the recommended dosage of
hawthorn in humans is 900 mg/day. This is
approximately 13 mg/kg/day for a 70-kg person.
As a result, we selected a human dose of 13
mg/kg as our middle dose and used doses 10-fold
higher and 10-fold lower to achieve a reasonable
dose-response range. Therefore, doses were 1.3
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(low), 13 (medium), or 130 (high) mg/kg.
Hawthorn was administered by oral gavage at
approximately 5:00 P.M.
After 1 week of aortic constriction, the initial
treatment groups consisted of the following:
sham operation–vehicle group (12 rats), aortic
constriction–vehicle group (15), aortic constric-
tion–low-dose group (17), aortic constriction–
medium-dose group (15), and aortic constric-
tion–high-dose group (15). We terminated the
study when the mortality rate reached
approximately 50% in any of the treated aortic-
constriction groups. Therefore, the study ended
at 5 months. The decision to terminate the trial
at a 50% mortality rate was made to ensure that
we had adequate power at the end of the study
and that a transition to decompensated heart
failure could occur. Before the study ended, we
conducted a final echocardiographic assessment.
Afterward, we euthanized the rats and excised
and dissected their hearts to collect the right
ventricle, septum, left ventricular free wall, left
atrium, and right atrium. Tissues were stored at -
80°C for subsequent isolation of RNA and
protein.
Aortic Constriction
Aortic constriction was conducted as described
previously.2 In brief, we performed left thoraco-
tomy with the animal under anesthesia induced
with pentobarbital 50 mg/kg and exposed the
ascending aorta. A Weck hemoclip was placed
around the ascending aorta 4–6 mm superior to
the aortic valve, with the gap of the Weck
hemoclip applicator set at 1.02 mm.
Outcome Measures
We assessed body and ventricular weights,
mortality rates, relative wall thickness, and
cardiac function (left ventricular dimension in
systole and diastole, stroke volume, velocity of
circumferential shortening, and fractional
shortening). In addition, we examined the
expression of messenger RNA (mRNA) for atrial
natriuretic factor (ANF), -myosin heavy chain,
and fibronectin, as well as the abundance of
collagen type III.
Echocardiography
We echocardiographically measured cardiac
function at baseline (1 wk before aortic
constriction) and at 2, 3, 4, and 5 months after
aortic constriction.13 Two-dimensional, guided,
M-mode recordings were obtained from the
short-axis view at the level of the papillary
muscles by using a system (Acuson Sequoia;
Siemens Medical Solutions, Malvern, PA)
equipped with a 15-MHz linear-array transducer
or a system (Vivid 7; GE Medical Systems,
Milwaukee, WI) equipped with a 10-MHz
phased-array transducer (S10-MHz; GE Medical
Systems).
For each M-mode measurement, at least three
consecutive cardiac cycles were sampled, as
previously described.13 A single echocardiographer
performed all measurements in accordance with
the conventions of the American Society of
Echocardiography.
Relative wall thickness was defined as 2 times
the thickness of the posterior wall in diastole
divided by the dimension of the left ventricle
during diastole. Relative wall thickness was used
instead of absolute wall thickness to facilitate
comparisons among rats because of inherent
variances from rat to rat.
RNA Blotting
Blotting for RNA was performed as described
previously, with modifications.2, 14 We isolated
RNA from the left ventricle and size-fractionated
10 µg of total RNA by electrophoresis through
1% agarose gels. Samples were transferred
electrophoretically at 5 V/cm to a nylon membrane
(Nytran SPC; Whatman Inc., Piscataway, NJ) and
hybridized with 32P-radiolabeled probes
overnight at 68°C for complementary DNA
probes and at 42–45°C for oligonucleotide probes
by using a hybridization buffer (PerfectHyb Plus;
Sigma-Aldrich Corp., St. Louis, MO).
Hybridization intensity was quantified with
a Personal Phosphorimager FX (Bio-Rad
Laboratories, Hercules, CA). Signals visualized
on computer screen were identified by their
position relative to migration of 18S and 28S
ribosomal RNA. They were delineated by
rectangles and quantified after subtracting the
background. Each blot was subsequently
stripped and reprobed. The signal from each
sample was normalized to the signal obtained
with an oligonucleotide specific for the 3′
untranslated region of glyceraldehyde-3 ′ -
phosphate dehydrogenase. The probe for -
myosin heavy chain was an oligonucleotide
described previously.14 Complementary DNA
probes for ANF and fibronectin were synthesized
from a template by the random prime method
(Promega Corp., Madison, WI).
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Immunoblotting for Collagen Type III
Portions of the frozen left ventricle were
processed for immunoblotting, as described
elsewhere.2 Relative levels of collagen type III
were measured protein using a monoclonal
antibody directed at collagen type III (Santa Cruz
Biotechnology, Santa Cruz, CA). Signals were
quantified by using enhanced chemiluminescence.
Statistical Analysis
Data are expressed as percentages or mean ±
standard error of the mean. Mortality rates were
determined by Kaplan-Meier analysis. End-point
variables were analyzed by using a 1-way analysis
of variance (ANOVA), and group differences were
determined with the least significant difference
post hoc procedure. Contrasts were performed to
compare the aortic constriction–vehicle group
with the three hawthorn dose groups combined
to determine the overall effect of hawthorn.
Echocardiographic data were analyzed by using
2-way ANOVA (group x time) with repeated
measures, and group differences were determined
with the least significant difference post hoc
procedure. When the interaction for group x
time was significant, a 1-way ANOVA procedure
with repeated measures was conducted for each
group separately, followed by the least significant
difference post hoc procedure to determine
differences between time points within a group.
Differences were considered statistically signifi-
cant when  was 0.05 or less.
Results
Forty-four rats survived to the end of the study
(5 mo): sham operation–vehicle group (12 rats),
aortic constriction–vehicle group (9), aortic
constriction–low-dose group (10), aortic
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Table 1. Postmortem Analysis During 5 Months of Pressure Overload by Treatment Groupa
Aortic Constriction
Hawthorn Hawthorn Hawthorn
Sham Operation, Low-Dose Medium-Dose High-Dose
Vehicle Group Vehicle Group Group Group Group
Variable (n=12) (n=9) (n=10) (n=6) (n=7) p Value
Mortality ratea 0% 40% (6/15) 41% (7/17) 60% (9/15) 53% (8/15) <0.05b
Mean ± SEM
Initial body weight (g) 262 ± 6.6 261 ± 8.5 253 ± 6 278 ± 8.9 269 ± 6.1 <0.01c
Final body weight (g) 561 ± 22 555 ± 22 554 ± 13 542 ± 35 536 ± 17 <0.01c
LV dry:LV wet ratio 0.23 ± 0.003 0.23 ± 0.002 0.22 ± 0.003 0.22 ± 0.005 0.22 ± 0.004 ≥0.05
(mg:mg)
RV:body weight ratio 0.51 ± 0.02 0.53 ± 0.02 0.62 ± 0.05 0.53 ± 0.03 0.55 ± 0.02 ≥0.05
(mg:g)
SEM = standard error of the mean; LV = left ventricular; RV = right ventricular.
aEnd-point variables were evaluated by using 1-way analysis of variance followed by the least significant difference post hoc procedure.
Mortality was determined by Kaplan-Meier analysis.
bFor all aortic-constriction groups vs sham operation–vehicle group.
cFor all comparisons over the course of the experiment.
Figure 1. Cardiac hypertrophy after 5 months of pressure
overload assessed as left ventricular (LV) mass (panel A) and
the LV:body weight ratio (panel B) at the end point of the
experiment. Data are mean ± standard error of the mean.
AC = aortic constriction. ap<0.05 vs sham operation–vehicle
group (1-way analysis of variance followed by the least
significant difference post hoc procedure).
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constriction–medium-dose group (6), and aortic
constriction–high-dose group (7). Increases in
body weight from before the operation to 5
months after the operation were similar in the
sham operation–vehicle group and aortic
constriction group–vehicle group. This result
indicated that neither hawthorn treatment nor
aortic constriction influenced the increase in
body weight that occurred over the course of the
experiment (Table 1).
After 5 months, left ventricular mass was 47%
greater in the aortic-constriction groups than in
the sham operation–vehicle group (p<0.05;
Figure 1A). Hawthorn treatment significantly
attenuated the increase in left ventricular mass
caused by aortic constriction. Aortic constriction
increased the left ventricular:body weight ratio
by 53% in vehicle-treated rats (p<0.001). The
influence of hawthorn on the aortic constriction–
induced increase in this ratio was not statistically
significant, although the trend was similar to
changes observed for left ventricular mass alone
(Figure 1B).
During 5 months of aortic constriction–induced
pressure overload, the mortality rate was 40% for
vehicle-treated rats. No significant differences
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Table 2. Structural and Functional Cardiac Adaptations in Response to Chronic Pressure Overload and Hawthorn
Treatment
Aortic Constriction
Hawthorn Hawthorn Hawthorn
Sham Operation, Low-Dose Medium-Dose High-Dose
Vehicle Group Vehicle Group Group Group Group
Measurea (n=12) (n=9) (n=10) (n=6) (n=7)
Stroke volume
(ml/beat)
Baseline 205 ± 19.4 197 ± 19.9 190 ± 17.7 192 ± 16.7 228 ± 26.0
Month 2 359 ± 25.4b 297 ± 40.2b 303 ± 34.2b 245 ± 33.5 282 ± 40.8
Month 3 371 ± 19.7b 388 ± 49.7b 382 ± 20.6b 303 ± 25.3b 306 ± 40.0
Month 4 429 ± 27.7b 296 ± 35.4b, c 361 ± 34.5b 289 ± 34.7b, c 335 ± 31.7c
Month 5 418 ± 24.0b 319 ± 17.4b, c 413 ± 36.1b 344 ± 32.2b 319 ± 52.5c
Percent changed +103 +62 +117 +79 +40
LV dimension,
diastole (mm)
Baseline 6.29 ± 0.23 6.20 ± 0.20 6.05 ± 0.21 6.25 ± 0.18 6.59 ± 0.21
Month 2 7.78 ± 0.21b 7.30 ± 0.34b 7.25 ± 0.38b 6.70 ± 0.37 6.99 ± 0.31
Month 3 7.81 ± 0.16b 7.84 ± 0.34b 7.87 ± 0.21b 7.07 ± 0.20b 7.20 ± 0.45
Month 4 8.15 ± 0.20b 7.30 ± 0.33b 7.81 ± 0.32b 7.05 ± 0.28b 7.44 ± 0.28
Month 5 8.26 ± 0.19b 7.58 ± 0.20b 8.20 ± 0.28b 7.72 ± 0.30b 7.20 ± 0.38
Percent changed +31 +22 +37 +24 +9
LV dimension,
systole (mm)
Baseline 3.71 ± 0.17 3.60 ± 0.13 3.25 ± 0.24 3.77 ± 0.17 3.94 ± 0.17
Month 2 4.88 ± 0.21b 4.59 ± 0.37b 4.33 ± 0.44b 3.83 ± 0.45 4.06 ± 0.26
Month 3 4.73 ± 0.19b 4.73 ± .034b 4.59 ± 0.36b 3.72 ± 0.23 4.07 ± 0.57
Month 4 4.85 ± 0.24b 4.54 ± 0.41b 4.78 ± 0.45b 3.95 ± 0.36 4.31 ± 0.30
Month 5 5.28 ± 0.21b 4.84 ± 0.29b 5.13 ± 0.37b 4.65 ± 0.58 4.07 ± 0.28
Percent changed +42 +34 +58 +23 +3
Fractional
shortening (%)
Baseline 40.8 ± 1.7 41.8 ± 0.3 47.1 ± 2.5 39.7 ± 2.3 40.0 ± 2.3
Month 2 37.5 ± 1.5 37.5 ± 3.3 41.2 ± 3.1 43.3 ± 4.1 41.9 ± 3.3
Month 3 39.6 ± 1.6 40.1 ± 2.9 42.1 ± 3.3 47.5 ± 2.6 44.6 ± 4.8
Month 4 40.7 ± 2.0 38.5 ± 3.7 39.6 ± 3.9 44.0 ± 4.3 42.3 ± 2.1
Month 5 36.3 ± 1.4 36.7 ± 2.4 37.7 ± 2.8 40.3 ± 5.4 43.3 ± 2.6
Percent changed -9 -12 -20 +2 +8
Data are mean ± standard error of the mean.
Baseline = 1 wk before aortic constriction.
aFor all measures, 2-way analysis of variance with a repeated-measures, least significant difference post hoc procedure yielded the
following p values: group p≥0.05, time p<0.01, and group x time p≥0.05.
bp<0.05 compared with baseline value within same treatment group.
cp<0.05 compared with sham operation–vehicle value at same time point.
dCalculated as (value at 5 months – baseline value)/baseline value.
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were seen when these rats were compared with
hawthorn-treated rats (Table 1). Aortic constric-
tion significantly increased relative wall thickness
by 40% in vehicle-treated rats. Over time, low-
and medium-dose hawthorn treatment signifi-
cantly diminished the increase in constriction-
induced relative wall thickness (Figure 2).
Left ventricular dimension in systole and
diastole significantly increased by greater than
20% over baseline in the aortic constriction–vehicle
group; however, no significant increase (< 10%)
was observed in the aortic constriction–high-
dose group (Table 2). Likewise, left ventricular
volumes at end of systole and end of diastole did
not significantly increase at 5 months after aortic
constriction in the aortic constriction–high-dose
group. Significant increases were observed in the
aortic constriction–vehicle group (Figure 3A and
3B). In aggregate, the data indicated that high-
dose hawthorn modified aortic constriction–
induced cardiac remodeling most significantly.
Aortic constriction attenuated the increase in
stroke volume that occurred over time in vehicle-
treated rats (Table 2). Constriction-induced
attenuation of the increase in stroke volume over
time was counteracted, especially by low and
medium doses of hawthorn. Velocity of circum-
ferential shortening significantly decreased in the
aortic constriction groups treated with vehicle or
low-dose hawthorn. However, medium and high
doses did not significantly lower velocity of
circumferential shortening after 5 months of
aortic constriction (Figure 3C).
644
Figure 2. Cardiac remodeling, assessed as relative wall
thickness, during 5 months of pressure overload. Data are
mean ± standard error of the mean. Data were analyzed by
using a 2-way analysis of variance with repeated measures
followed by the least significant difference post hoc
procedure. AC = aortic constriction; baseline = 1 week before
AC. ap<0.05 vs sham operation–vehicle group at 5 months;
bp<0.05 vs aortic constriction–vehicle group at 5 months.
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Figure 3. Cardiac function during 5 months of pressure
overload evaluated as left ventricular volume (LV) at end of
systole (panel A), left ventricular volume at end of diastole
(panel B), and velocity of circumferential shortening in the
left ventricle (panel C). Data are mean ± standard error of
the mean. Data were analyzed by using a 2-way analysis of
variance with repeated measures followed by the least
significant difference post hoc procedure. AC = aortic
constriction; baseline = 1 week before AC. ap<0.05 vs
baseline within the same treatment group.
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For the sham operation–vehicle, aortic
constriction–vehicle, and aortic constriction–
low-dose groups, fractional shortening was lower
at 5 months compared with baseline (Table 2).
In contrast, fractional shortening seemed to
improve in the medium- and high-dose groups.
Overall, the data suggested that hawthorn given
at a high dose maintained cardiac function better
than vehicle after 5 months of aortic constriction.
At 5 months, levels of ANF mRNA significantly
rose by 1000% in the hearts of rats who received
aortic constriction and vehicle (Figure 4A). Each
dose of hawthorn almost completely counteracted
the increase in ANF mRNA caused by long-term
aortic constriction. At 5 months after sham
operation or aortic constriction, levels of mRNA
for -myosin heavy chain did not significantly
differ among any of the five groups (Figure 4B).
After pressure overload, expression of fibronectin
mRNA in the left ventricle significantly increased
by 78% (Figure 4C). Each of the three doses of
hawthorn markedly attenuated the aortic con-
striction–induced increase in mRNA expression
for fibronectin.
The abundance of collagen type III protein was
significantly and similarly elevated in the three
aortic constriction groups treated with vehicle or
medium or high doses of hawthorn compared
with the sham operation–vehicle group (Figure
5). Collagen type III protein levels in the aortic
constriction–low-dose group were not significantly
greater than those of the sham-vehicle group, but
they were also not significantly lower than the
aortic constriction–vehicle levels. Taken together,
these data showed that hawthorn treatment had
little, if any, effect on the aortic constriction–induced
increase in the abundance of collagen III protein.
Discussion
Our survival data indicate that our model of
pressure overload likely caused a progression of
heart failure, which increased mortality rates in
rats undergoing aortic constriction compared
with those receiving sham operation plus vehicle.
The most potent effects of hawthorn were
observed for variables that reflected the nature of
cardiac remodeling. These included marked
suppression of the aortic constriction–induced
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Figure 4. Expression of hypertrophy-associated messenger
RNA in the left ventricle for atrial natriuretic factor (panel A),
-myosin heavy chain (panel B), and fibronectin (panel C).
Data are mean ± standard error of the mean. AC = aortic
constriction. Brackets indicate contrasts for the AC-vehicle
group vs the AC–low-dose, AC–medium-dose, and AC–high-
dose groups combined. ap<0.05 vs sham operation–vehicle
group (1-way analysis of variance followed by the least
significant difference post hoc procedure).
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Figure 5. Abundance of collagen type III protein in the left
ventricle after 5 months. Levels were measured by
immunoblotting and normalized to the signal for
glyceraldehyde-3′-phosphate dehydrogenase (GAPDH).
Data are mean ± standard error of the mean. AC = aortic
constriction. ap<0.05 vs sham operation–vehicle group (1-
way analysis of variance followed by the least significant
difference post hoc procedure).
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increase in mRNA expression for ANF and
fibronectin, as well as alterations in structural
remodeling. All doses of hawthorn positively
influenced ANF and fibronectin mRNA expres-
sion. At the highest dose, hawthorn favorably
affected ventricular size and systolic function.
The results suggest that hawthorn exerted
important effects on remodeling and on the
progression of heart failure in a pressure overload
model of heart failure.
To our knowledge, this was the first study to
show that hawthorn treatment influences cardiac
remodeling in the context of long-term pressure
overload. Hawthorn attenuated the increase in
left ventricular mass after aortic constriction.
Although the left ventricular:body weight ratio
was not significantly attenuated, the trend was
similar to that observed with left ventricular
mass. Given other findings for remodeling
parameters, although the trend is not statistically
significant, it is likely to be clinically significant.
The mean percentage increase in left ventricular
systolic and diastolic dimensions was less than
10% (p>0.05 vs baseline) in the high-dose
hawthorn group after 5 months of aortic
constriction compared with an increase of greater
than 20% (p<0.05 vs baseline) in the aortic
constriction–vehicle group. We noted similar
findings regarding left ventricular systolic and
diastolic volumes. In support of these results,
ANF expression, which increases in response to
pressure and stretch, was significantly lower in
the hawthorn groups than in the aortic con-
striction–vehicle group.
Possible mechanisms for the benefits of
hawthorn on cardiac remodeling are likely
multifactorial given its wide range of reported
effects on the myocardium and on signaling
pathways. These include inotropic actions on
cardiac muscle that may indirectly benefit
remodeling of the heart, as well as a vasodilatory
property of hawthorn that may be attributed to
nitric oxide.15, 16 Another factor to consider is
that hawthorn exhibited protective effects against
ischemia-reperfusion injury by conferring
mitochondrial protection.17, 18 If true, prevention
of mitochondrial damage and apoptosis would be
consistent with improved remodeling because it
would prevent loss of myocytes that can lead to
weakening and fibrosis.
Additional mechanisms—or mechanisms that
may explain the observed effects of hawthorn—
may also be proposed on the basis of observed
effects of the agent or its individual constituents
(flavonoids and polyphenolic compounds).
These additional mechanisms may include effects
on reactive oxygen species, nitric oxide (endothelial
and inducible nitric oxide synthases), and specific
signaling pathways involving p38 mitogen-
activated protein kinase, nuclear factor– B, and
extracellular signal-regulated kinases 1 and 2.19–26
The intrinsic ability of the ventricles to contract
was maintained most with the medium and high
doses of hawthorn after aortic constriction, as
evidenced by the lack of change in the velocity of
circumferential shortening and fractional
shortening. By comparison, these parameters
decreased in the vehicle and low-dose groups
after aortic constriction. These findings were
consistent with our observations regarding
ventricular remodeling in this study. Together,
the data suggest that hawthorn may attenuate the
transition from compensated to decompensated
heart failure after long-term pressure overload.
The apparent effects of hawthorn to lessen a
maladaptive form of hypertrophy that we found
were consistent with our previous results from a
short-term model of pressure overload.12 In that
model, hawthorn maintained a more adaptive
form of hypertrophy after aortic constriction than
vehicle, on the basis of the velocity of circum-
ferential shortening and relative wall thickness.
Potential mechanisms to account for the effects
on systolic function include beneficial effects on
apoptosis, reactive oxygen species, endothelial
nitric oxide synthase, and inducible nitric oxide
synthase, along with inotropic actions of hawthorn.
Previous studies have shown that hawthorn
increases the inotropic activity of cardiac muscle.15
Moreover, treatment of failing human myocardium
with hawthorn increases both the calcium ion–
transient and the force production of papillary
muscles from these hearts. The mechanism of
these inotropic effects is partly attributed to the
ability of hawthorn to inhibit Na+-K+–adenosine
5′-triphosphatase.15
Many studies have shown that ANF mRNA
levels increase in response to a wide range of
hypertrophic stimuli, including aging, long-term
-adrenergic stimulation, aortic constriction,
thyroid hormone, hypertension, exercise training,
and coronary artery occlusion.27, 28 Therefore,
repeat induction of gene expression for ANF in
the left ventricle is one of the most reliable
markers of cardiac hypertrophy. Levels of ANF
mRNA were significantly elevated in spon-
taneously hypertensive rats compared with
normotensive Wistar-Kyoto rats and increased
even further when hypertension-induced
hypertrophy progressed to heart failure.14 In the
646
EFFECT OF HAWTHORN ON HEART FAILURE IN A RAT MODEL Bleske et al
present study, hawthorn almost completely
abolished the increase in ANF mRNA levels
caused by 5 months of pressure overload. These
data helped confirm our findings that hawthorn
significantly affects ventricular remodeling.
Excessive accumulation of proteins of the
extracellular matrix, fibronectin, and collagen
causes myocardial fibrosis that results in
stiffening of the heart and diastolic dysfunction.29
Type III collagen is one of the two major types of
collagen expressed in the heart. Type III collagen
accounts for approximately 20% of the total
collagen in rat heart tissue. Levels of mRNA for
collagen type III are transiently elevated in the
heart after aortic constriction in chronic hyper-
tension and during the transition from compen-
sated hypertrophy to heart failure.2, 5, 14 Fibronectin
is a large protein of the extracellular matrix that
binds together various components and cells of
the matrix, contributing to its overall integrity.
Fibronectin gene expression increases in response
to advancing age, aortic constriction, chronic hyper-
tension, cardiomyopathy, and heart failure.4, 5, 13, 14
In our study, 5 months of aortic constriction
increased levels of type III collagen by 35% and
increased fibronectin mRNA levels by 78%,
consistent with previous findings.2, 5, 6 Hawthorn
treatment did not significantly attenuate the
aortic constriction–induced increase in type III
collagen protein. Hawthorn did, however,
attenuate the constriction-induced increase in
fibronectin mRNA expression, suggesting that it
may have modified the nature of extracellular
matrix to some extent. The lack of effect on the
abundance of collagen type III protein suggests
that hawthorn did not mitigate the aortic con-
striction–induced increase in the total amount of
extracellular matrix. Effects of hawthorn on
fibronectin expression may contribute, at least in
part, to modest changes in end-diastolic
dimension and volume, as we observed in some
of the hawthorn-treated groups.
One obvious limitation was that this investi-
gation was an animal study and that mechanisms
for the results found were not well defined.
However, ANF was suppressed in the hawthorn-
treated groups, and this finding appears to
confirm our results regarding structural
remodeling. Another limitation was that this was
not a mortality trial; therefore, inferences from
our mortality results are limited. Although
mortality rates seemed to be higher in the
hawthorn groups than in the others, we found no
clear dose response, and these findings were
likely the result of chance. Given the few
animals studied, one death can dramatically alter
interpretation of the data.
Also of note, echocardiography was performed
at five time points, and data for rats that died
before the 5-month end point were excluded
from the final analysis. When we examined the
last echocardiographic measurements obtained
from rats that died before this point, we noted no
obvious indications of heart failure (e.g., marked
reduction in fractional shortening or left
ventricular ejection fraction). Autopsies were
not conducted for rats that died before the end-
point analysis. Therefore, although heart failure
due to pressure overload was the assumed cause
of death, no autopsy or echocardiographic data
were available to confirm this assumption.
From a clinical perspective, a potential limitation
of this study was the fact that hawthorn was not
administered with standard-of-care therapies
such as ACE inhibitors and -blockers. On the
other hand, this design might actually have been
the strength of the study in that hawthorn could
demonstrate its effects on the progression of
heart failure. One can easily reason that powerful
remodeling drugs such as ACE inhibitors and -
blockers may mask or attenuate the effects of
hawthorn on remodeling. In clinical terms, this
may have important therapeutic implications,
particularly in patients who cannot tolerate or
who are not candidates for standard-of-care ACE
inhibition or -blockade. Because hawthorn has
shown remodeling effects similar to those of both
these treatments, high-risk patients who cannot
receive this standard of care are most likely to
benefit from hawthorn therapy, especially with
regard to ventricular remodeling. Perhaps an
important niche for complementary and alternative
medicine may be the treatment of patients who
cannot tolerate or who are not candidates for
standard approaches.
Conclusion
Our data suggest that hawthorn attenuates
maladaptive ventricular remodeling and
decreases in systolic function associated with
longstanding pressure overload. Of note, these
findings are consistent with the observation that
hawthorn attenuates increases in ANF, a marker
related to cardiac hypertrophy, and in fibronectin,
a marker associated with fibrosis. Our study
demonstrated the importance of herbal therapy
in a rat model of heart failure. Further studies in
humans are now warranted to determine the
effect of hawthorn on ventricular remodeling.
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